DE60234329D1 - Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2 - Google Patents

Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2

Info

Publication number
DE60234329D1
DE60234329D1 DE60234329T DE60234329T DE60234329D1 DE 60234329 D1 DE60234329 D1 DE 60234329D1 DE 60234329 T DE60234329 T DE 60234329T DE 60234329 T DE60234329 T DE 60234329T DE 60234329 D1 DE60234329 D1 DE 60234329D1
Authority
DE
Germany
Prior art keywords
phospholipase
group
cyclooxigenase
inhibitors
lipid molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234329T
Other languages
English (en)
Inventor
Brian Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biozone Laboratories Inc
Original Assignee
Biozone Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26959001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60234329(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biozone Laboratories Inc filed Critical Biozone Laboratories Inc
Application granted granted Critical
Publication of DE60234329D1 publication Critical patent/DE60234329D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)
DE60234329T 2001-03-23 2002-03-22 Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2 Expired - Lifetime DE60234329D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27825701P 2001-03-23 2001-03-23
US09/877,334 US6495596B1 (en) 2001-03-23 2001-06-07 Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
PCT/US2002/011155 WO2002102757A1 (en) 2001-03-23 2002-03-22 Glycerol-peg-derivatives as inhibitors of cyclooxygenase-2 and phospholipase-a2

Publications (1)

Publication Number Publication Date
DE60234329D1 true DE60234329D1 (de) 2009-12-24

Family

ID=26959001

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234329T Expired - Lifetime DE60234329D1 (de) 2001-03-23 2002-03-22 Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2

Country Status (6)

Country Link
US (1) US6495596B1 (de)
EP (1) EP1381587B1 (de)
AT (1) ATE448189T1 (de)
CA (1) CA2447811C (de)
DE (1) DE60234329D1 (de)
WO (1) WO2002102757A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US6998421B2 (en) * 2001-06-07 2006-02-14 Biozone Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase - 2
US20030166716A1 (en) * 2001-11-06 2003-09-04 Serhan Charles N. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US20050106122A1 (en) * 2002-02-25 2005-05-19 Sveinbjorn Gizurarson Absorption enhancing agent
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
JP2006518701A (ja) * 2002-05-24 2006-08-17 ネオファーム、インコーポレイティッド カルジオリピン組成物、その製造方法及び使用
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
MXPA06012070A (es) * 2004-04-20 2007-04-24 Univ Chicago Sistema de surtido terapeutico que comprende un compuesto de tipo peg de peso molecular alto.
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
US7282224B1 (en) 2006-06-09 2007-10-16 Guthy-Renker Corporation Pain relief composition
US20080107747A1 (en) * 2006-10-23 2008-05-08 Roederer Joy E Pain relief composition
BRPI0808660A2 (pt) * 2007-03-08 2014-08-19 Crescendo Thetapeutics Llc Formulações de curativo para prevenir e reduzir a formação de cicatriz
WO2009105294A2 (en) * 2008-02-20 2009-08-27 Elc Management Llc Topical compositions and methods for whitening skin
WO2011006100A1 (en) * 2009-07-09 2011-01-13 Crescendo Therapeutics, Llc Method of wound healing and scar modulation
CN106290351A (zh) * 2015-06-03 2017-01-04 舒泰神（北京）生物制药股份有限公司 一种磷脂酶a2的活性测定方法
US10702475B2 (en) 2017-09-05 2020-07-07 Richard Rigg Liposome containing compositions and their use in personal care and food products
JP6805385B1 (ja) * 2020-08-31 2020-12-23 ジェイ−ネットワーク，インコーポレイテッド 表皮内の保湿関連物質の発現増強剤
JP6860739B1 (ja) 2020-11-20 2021-04-21 ジェイ−ネットワーク，インコーポレイテッド 表皮内の抗酸化物質の発現増強剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001234A (en) 1987-04-16 1991-03-19 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5659049A (en) 1988-02-18 1997-08-19 Virginia Commonwealth University Antioxidant, antiphospholipase derivatives of ricinoleic acid
US5122536A (en) 1989-10-12 1992-06-16 Perricone Nicholas V Method for the topical treatment of psoriasis
JPH04134077A (ja) 1990-09-21 1992-05-07 Taiho Yakuhin Kogyo Kk イソオキサゾール化合物
JPH07504887A (ja) 1991-11-22 1995-06-01 リポジェニックス，インコーポレイテッド トコトリエノールおよびトコトリエノール様化合物ならびにこれらを使用する方法
US5451686A (en) 1994-04-15 1995-09-19 Allergan, Inc. 3 and 5 alkyl and phenyl 4-(hydroxy or acyloxy)-alkyl substituted 2(5H)-furanones as anti-inflammatory agents
FR2750426B1 (fr) 1996-06-28 1998-08-07 Cird Galderma Nouveaux composes biaryles heterocycliques et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetique
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
DE19909552C1 (de) * 1999-03-04 2000-07-27 Goldwell Gmbh Haarwaschmittel

Also Published As

Publication number Publication date
CA2447811A1 (en) 2002-12-27
EP1381587A1 (de) 2004-01-21
CA2447811C (en) 2011-11-29
US6495596B1 (en) 2002-12-17
ATE448189T1 (de) 2009-11-15
WO2002102757A1 (en) 2002-12-27
EP1381587B1 (de) 2009-11-11
US20020198260A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
DE60234329D1 (de) Glycerin-peg-derivate als inhibitoren der cyclooxigenase-2 und der phospholipase-a2
Da Cunha et al. Caffeic acid derivatives: in vitro and in vivo anti-inflammatory properties
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
BR0008188A (pt) Inibidores de fator de diferenciação de crescimento e usos para os mesmos
ECSP10010735A (es) Compuestos químicos 251
MA31167B1 (fr) Inhibiteurs de l'activite de akt
DK1754707T3 (da) Multicykliske forbindelser og anvendelse deraf som inhibitorer af PARP-, VEGFR2- og MLK3-enzymer
BRPI0518228B8 (pt) inibidores de cinesina mitótica e uso dos mesmos
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
BRPI0513916A (pt) moduladores de pirrol-piridina cinase
ES2194501T3 (es) Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
MX2008010462A (es) Inhibidores de histona desacetilasa.
UY27362A1 (es) Métodos de usar inhibidores de epóxido hidrolasa soluble
PT1206474E (pt) Compostos de sulfonilfenilpirazole uteis como inibidores de cox-2
BR0308967A (pt) Derivados de quinolina e isoquinolina, um processo para a sua preparação e sua aplicação como inibidores de inflamação
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
CY1111086T1 (el) Παραγωγα 2-αμινο-κιναζολινης χρησιμα ως αναστολεις της βητα-σεκρετασης (bace)
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
ES2193949T3 (es) Nuevos derivados del acido lipoico, su preparacion y composiciones farmaceuticas que los contienen.
MA30321B1 (fr) Principe actif cosmetique compose de ferrulate d'arginine et d'un extrait de microalgue et ses utilisations
BRPI0507626A (pt) compostos e composiçoes como moduladores de lxr
UY30918A1 (es) Moduladores de lta4h y sus usos
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition